Xenon Pharmaceuticals Inc [XENE] stock prices are down -2.15% to $36.95 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The XENE shares have gain 2.04% over the last week, with a monthly amount drifted -1.83%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Chardan Capital Markets started tracking the stock with Buy rating on May 07, 2025, and set its price target to $55. On February 11, 2025, Deutsche Bank initiated with a Buy rating and assigned a price target of $67 on the stock. H.C. Wainwright initiated its recommendation with a Buy and recommended $53 as its price target on October 01, 2024. Citigroup started tracking with a Buy rating for this stock on January 04, 2024, and assigned it a price target of $62. In a note dated December 08, 2023, Robert W. Baird initiated an Outperform rating and provided a target price of $63 on this stock.
The stock price of Xenon Pharmaceuticals Inc [XENE] has been fluctuating between $26.74 and $46.00 over the past year. Currently, Wall Street analysts expect the stock to reach $50.63 within the next 12 months. Xenon Pharmaceuticals Inc [NASDAQ: XENE] shares were valued at $36.95 at the most recent close of the market. An investor can expect a potential return of 37.02% based on the average XENE price forecast.
Analyzing the XENE fundamentals
Gross Profit Margin for this corporation currently stands at 0.74% with Operating Profit Margin at -31.76%, Pretax Profit Margin comes in at -28.21%, and Net Profit Margin reading is -27.78%. To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is -0.39 and Total Capital is -0.5. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Xenon Pharmaceuticals Inc [NASDAQ:XENE]’s Current Ratio is 15.14. On the other hand, the Quick Ratio is 15.14, and the Cash Ratio is 4.1. Considering the valuation of this stock, the price to sales ratio is 379.87, the price to book ratio is 4.48.
Transactions by insiders
Recent insider trading involved SHERRY AULIN, Former officer, that happened on Sep 19 ’25 when 2548.0 shares were purchased. Director, GANNON STEVEN completed a deal on Jun 05 ’25 to sell 3.0 shares. Meanwhile, PRESIDENT & CEO MORTIMER IAN sold 22468.0 shares on Jan 24 ’25.
